BR112014007622A2 - inibidores de flt3 cinase macrocíclicos - Google Patents
inibidores de flt3 cinase macrocíclicosInfo
- Publication number
- BR112014007622A2 BR112014007622A2 BR112014007622A BR112014007622A BR112014007622A2 BR 112014007622 A2 BR112014007622 A2 BR 112014007622A2 BR 112014007622 A BR112014007622 A BR 112014007622A BR 112014007622 A BR112014007622 A BR 112014007622A BR 112014007622 A2 BR112014007622 A2 BR 112014007622A2
- Authority
- BR
- Brazil
- Prior art keywords
- macrocyclic
- kinase inhibitors
- flt3 kinase
- flt3
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Abstract
resumo patente de invenção: "inibidores de flt3 cinase macrocíclicos". a presente invenção refere-se a compostos macrocíclicos e composições contendo os referidos compostos agindo como inibidores de cinase, em particular como inibidores de flt3 (tirosina cinase 3 relacionada com fms). além disso, a presente invenção fornece processos para a preparação de compostos descritos, bem como métodos de utilizá-los, por exemplo, como um medicamento, em particular para o tratamento de distúrbios proliferativos celulares, tal como câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2011067084 | 2011-09-30 | ||
PCT/EP2012/069252 WO2013045653A1 (en) | 2011-09-30 | 2012-09-28 | Macrocyclic flt3 kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014007622A2 true BR112014007622A2 (pt) | 2017-04-04 |
Family
ID=46980944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014007622A BR112014007622A2 (pt) | 2011-09-30 | 2012-09-28 | inibidores de flt3 cinase macrocíclicos |
Country Status (14)
Country | Link |
---|---|
US (2) | US9090630B2 (pt) |
JP (1) | JP6046728B2 (pt) |
KR (1) | KR20140078710A (pt) |
CN (1) | CN103930427B (pt) |
AU (1) | AU2012314376B2 (pt) |
BR (1) | BR112014007622A2 (pt) |
CA (1) | CA2849999A1 (pt) |
DK (1) | DK2760867T3 (pt) |
EA (1) | EA025881B1 (pt) |
ES (1) | ES2569048T3 (pt) |
HK (1) | HK1198764A1 (pt) |
HU (1) | HUE027318T2 (pt) |
MX (1) | MX347765B (pt) |
WO (1) | WO2013045653A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2760453T (pt) * | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
KR20150133765A (ko) * | 2013-03-15 | 2015-11-30 | 온코디자인 에스.에이. | 거대고리 rip2 키나제 억제제 |
US9586975B2 (en) * | 2013-03-15 | 2017-03-07 | Oncodesign S.A. | Macrocyclic salt-inducible kinase inhibitors |
ES2635021T3 (es) * | 2013-03-15 | 2017-10-02 | Oncodesign S.A. | Inhibidores macrocíclicos de la LRRK2 quinasa |
ES2637721T3 (es) * | 2013-05-06 | 2017-10-16 | Merck Patent Gmbh | Macrociclos como inhibidores de quinasa |
EA031863B1 (ru) | 2014-01-24 | 2019-03-29 | ТиПи ТЕРАПЬЮТИКС, ИНК. | Диарильные макроциклы в качестве модуляторов протеинкиназ |
WO2015136073A1 (en) * | 2014-03-14 | 2015-09-17 | Oncodesign Sa | Macrocyclic tgf-br2 kinase inhibitors |
EP3172213B1 (en) * | 2014-07-21 | 2021-09-22 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
WO2016014542A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
AU2015300782B2 (en) | 2014-08-08 | 2020-04-16 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (SIK) inhibitors |
AU2015316799B2 (en) * | 2014-09-17 | 2019-07-11 | Oncodesign Precision Medicine (OPM) | Macrocyclic RIP2 kinase inhibitors |
PL3194405T3 (pl) * | 2014-09-17 | 2019-07-31 | Oncodesign S.A. | Makrocykliczne inhibitory kinazy lrrk2 |
WO2016146651A1 (en) | 2015-03-16 | 2016-09-22 | Oncodesign Sa | Macrocyclic activin-like receptor kinase inhibitors |
CN107735399B (zh) | 2015-07-02 | 2021-01-26 | 特普医药公司 | 作为蛋白质激酶的调节剂的手性二芳基大环 |
CN113354653A (zh) | 2015-07-06 | 2021-09-07 | 特普医药公司 | 二芳基大环多晶型物及其制备方法 |
BR112018001065A2 (pt) | 2015-07-21 | 2018-09-11 | Tp Therapeutics, Inc. | macrociclos diarila quirais e usos dos mesmos |
RU2630958C2 (ru) * | 2015-12-29 | 2017-09-15 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) | Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения |
KR20190075043A (ko) | 2016-07-05 | 2019-06-28 | 더 브로드 인스티튜트, 인코퍼레이티드 | 비시클릭 우레아 키나제 억제제 및 그의 용도 |
TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Tp生物醫藥公司 | 巨環激酶抑制劑 |
WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
RU2019129727A (ru) | 2017-02-28 | 2021-03-30 | Зэ Дженерал Хоспитал Корпорэйшн | Применения пиримидопиримидинонов в качестве ингибиторов sik |
KR102645316B1 (ko) | 2017-07-28 | 2024-03-07 | 터닝 포인트 테라퓨틱스, 인크. | 거대환형 화합물 및 이의 용도 |
JOP20200152A1 (ar) | 2017-12-19 | 2022-10-30 | Turning Point Therapeutics Inc | مركبات حلقية كبرى لعلاج مرض |
CN110950889B (zh) * | 2018-09-27 | 2022-04-05 | 北京赛林泰医药技术有限公司 | 一种多靶点激酶抑制剂及其制备方法和用途 |
CA3163735A1 (en) * | 2019-12-03 | 2021-06-10 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
PT721331E (pt) | 1993-10-01 | 2002-05-31 | Astrazeneca Ab | Processo i |
US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
AU2003280599A1 (en) | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
BRPI0617489A2 (pt) | 2005-10-18 | 2011-07-26 | Janssen Pharmaceutica Nv | compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase |
WO2008016665A2 (en) | 2006-08-02 | 2008-02-07 | Xanthus Pharmaceuticals, Inc. | Imidazoacridine compounds for treating flt3 -mediated disorders |
US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
KR101546493B1 (ko) * | 2006-11-06 | 2015-08-21 | 톨레로 파마수티컬스, 인크. | 이미다조[1,2-b]피리다진 및 피라졸로[1,5-a]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도 |
WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
WO2009017795A1 (en) | 2007-08-02 | 2009-02-05 | Xanthus Pharmaceuticals, Inc. | Indazole compounds for treating inflammatory disorders, demyelinating disorders and cancers |
EP2252616B1 (en) | 2008-01-30 | 2014-07-23 | Genentech, Inc. | Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
CN101239978A (zh) | 2008-03-05 | 2008-08-13 | 南方医科大学 | 一种咪唑并吡啶类化合物 |
US8507488B2 (en) * | 2008-05-13 | 2013-08-13 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
PT2760453T (pt) * | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
-
2012
- 2012-09-28 WO PCT/EP2012/069252 patent/WO2013045653A1/en active Application Filing
- 2012-09-28 CA CA2849999A patent/CA2849999A1/en not_active Abandoned
- 2012-09-28 BR BR112014007622A patent/BR112014007622A2/pt not_active IP Right Cessation
- 2012-09-28 US US14/347,750 patent/US9090630B2/en not_active Expired - Fee Related
- 2012-09-28 ES ES12769084.0T patent/ES2569048T3/es active Active
- 2012-09-28 EA EA201490707A patent/EA025881B1/ru not_active IP Right Cessation
- 2012-09-28 JP JP2014532414A patent/JP6046728B2/ja not_active Expired - Fee Related
- 2012-09-28 MX MX2014003807A patent/MX347765B/es active IP Right Grant
- 2012-09-28 CN CN201280055769.2A patent/CN103930427B/zh not_active Expired - Fee Related
- 2012-09-28 HU HUE12769084A patent/HUE027318T2/en unknown
- 2012-09-28 KR KR1020147011451A patent/KR20140078710A/ko not_active Application Discontinuation
- 2012-09-28 DK DK12769084.0T patent/DK2760867T3/en active
- 2012-09-28 AU AU2012314376A patent/AU2012314376B2/en not_active Ceased
-
2014
- 2014-12-05 HK HK14112275.5A patent/HK1198764A1/zh not_active IP Right Cessation
-
2015
- 2015-06-19 US US14/744,154 patent/US9370519B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP6046728B2 (ja) | 2016-12-21 |
US20150283141A1 (en) | 2015-10-08 |
US20140303159A1 (en) | 2014-10-09 |
EA201490707A1 (ru) | 2014-08-29 |
WO2013045653A1 (en) | 2013-04-04 |
AU2012314376A1 (en) | 2014-05-15 |
MX347765B (es) | 2017-05-12 |
HK1198764A1 (zh) | 2015-06-05 |
KR20140078710A (ko) | 2014-06-25 |
JP2014528398A (ja) | 2014-10-27 |
HUE027318T2 (en) | 2016-10-28 |
DK2760867T3 (en) | 2016-04-11 |
AU2012314376B2 (en) | 2017-04-06 |
US9370519B2 (en) | 2016-06-21 |
EA025881B1 (ru) | 2017-02-28 |
MX2014003807A (es) | 2015-01-12 |
ES2569048T3 (es) | 2016-05-06 |
CN103930427A (zh) | 2014-07-16 |
US9090630B2 (en) | 2015-07-28 |
CN103930427B (zh) | 2016-03-09 |
CA2849999A1 (en) | 2013-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014007622A2 (pt) | inibidores de flt3 cinase macrocíclicos | |
PH12015502615B1 (en) | Chemical compounds | |
ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
NZ700928A (en) | Dna-pk inhibitors | |
EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
EA201391390A1 (ru) | Циклопропиламины в качестве ингибиторов lsd | |
IN2014MN00988A (pt) | ||
MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
BR112014008045A2 (pt) | benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas | |
EA201490888A1 (ru) | Новые производные пурина и их применение для лечения заболевания | |
MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
NI201500096A (es) | Compuesto químicos | |
IN2015DN01151A (pt) | ||
BR112014002245A2 (pt) | derivados de piridin-2(1h)-ona como inibidores de jak | |
BR112014029708A8 (pt) | Composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina | |
GB201302704D0 (en) | Therapeutic compounds | |
MX341577B (es) | Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero. | |
EA201491878A1 (ru) | Замещенные ксантиновые производные | |
MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
AU2012312301A8 (en) | Compounds useful as inhibitors of choline kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |